Fludarabine	B:C0059985
,	O
cyclophosphamide	O
and	O
lenalidomide	O
in	O
patients	O
with	O
relapsed	O
/	O
refractory	O
chronic	O
lymphocytic	I:C0023434
leukemia	I:C0023434
.	O

Fludarabine	O
,	O
cyclophosphamide	B:C0010583
and	O
lenalidomide	O
in	O
patients	O
with	O
relapsed	O
/	O
refractory	O
chronic	O
lymphocytic	I:C0023434
leukemia	I:C0023434
.	O

Fludarabine	O
,	O
cyclophosphamide	O
and	O
lenalidomide	B:C1144149
in	O
patients	O
with	O
relapsed	O
/	O
refractory	O
chronic	O
lymphocytic	I:C0023434
leukemia	I:C0023434
.	O

Fludarabine	O
,	O
cyclophosphamide	O
and	O
lenalidomide	O
in	O
patients	O
with	O
relapsed	O
/	O
refractory	O
chronic	B:C0023434
lymphocytic	I:C0023434
leukemia	I:C0023434
.	O

A	O
multicenter	B:C0206012
phase	I:C0206012
I	I:C0206012
-	I:C0206012
II	I:C0206012
GIMEMA	I:C0206012
trial	I:C0206012
.	O

The	O
activity	O
and	O
safety	O
of	O
a	O
regimen	B:C0040808
combining	O
lenalidomide	O
with	O
fludarabine	O
and	I:C0280920
cyclophosphamide	I:C0280920
(	O
fludarabine	O
and	I:C0280920
cyclophosphamide	I:C0280920
)	O
was	O
investigated	O
in	O
patients	O
with	O
relapsed	O
/	O
refractory	O
(	O
R/R	O
)	O
chronic	O
lymphocytic	I:C0023434
leukemia	I:C0023434
(	O
chronic	O
lymphocytic	I:C0023434
leukemia	I:C0023434
)	O
.	O

The	O
activity	O
and	O
safety	O
of	O
a	O
regimen	O
combining	O
lenalidomide	B:C1144149
with	O
fludarabine	O
and	I:C0280920
cyclophosphamide	I:C0280920
(	O
fludarabine	O
and	I:C0280920
cyclophosphamide	I:C0280920
)	O
was	O
investigated	O
in	O
patients	O
with	O
relapsed	O
/	O
refractory	O
(	O
R/R	O
)	O
chronic	O
lymphocytic	I:C0023434
leukemia	I:C0023434
(	O
chronic	O
lymphocytic	I:C0023434
leukemia	I:C0023434
)	O
.	O

The	O
activity	O
and	O
safety	O
of	O
a	O
regimen	O
combining	O
lenalidomide	O
with	O
fludarabine	B:C0280920
and	I:C0280920
cyclophosphamide	I:C0280920
(	O
fludarabine	O
and	I:C0280920
cyclophosphamide	I:C0280920
)	O
was	O
investigated	O
in	O
patients	O
with	O
relapsed	O
/	O
refractory	O
(	O
R/R	O
)	O
chronic	O
lymphocytic	I:C0023434
leukemia	I:C0023434
(	O
chronic	O
lymphocytic	I:C0023434
leukemia	I:C0023434
)	O
.	O

The	O
activity	O
and	O
safety	O
of	O
a	O
regimen	O
combining	O
lenalidomide	O
with	O
fludarabine	O
and	I:C0280920
cyclophosphamide	I:C0280920
(	O
fludarabine	B:C0280920
and	I:C0280920
cyclophosphamide	I:C0280920
)	O
was	O
investigated	O
in	O
patients	O
with	O
relapsed	O
/	O
refractory	O
(	O
R/R	O
)	O
chronic	O
lymphocytic	I:C0023434
leukemia	I:C0023434
(	O
chronic	O
lymphocytic	I:C0023434
leukemia	I:C0023434
)	O
.	O

The	O
activity	O
and	O
safety	O
of	O
a	O
regimen	O
combining	O
lenalidomide	O
with	O
fludarabine	O
and	I:C0280920
cyclophosphamide	I:C0280920
(	O
fludarabine	O
and	I:C0280920
cyclophosphamide	I:C0280920
)	O
was	O
investigated	O
in	O
patients	O
with	O
relapsed	O
/	O
refractory	O
(	O
R/R	O
)	O
chronic	B:C0023434
lymphocytic	I:C0023434
leukemia	I:C0023434
(	O
chronic	O
lymphocytic	I:C0023434
leukemia	I:C0023434
)	O
.	O

The	O
activity	O
and	O
safety	O
of	O
a	O
regimen	O
combining	O
lenalidomide	O
with	O
fludarabine	O
and	I:C0280920
cyclophosphamide	I:C0280920
(	O
fludarabine	O
and	I:C0280920
cyclophosphamide	I:C0280920
)	O
was	O
investigated	O
in	O
patients	O
with	O
relapsed	O
/	O
refractory	O
(	O
R/R	O
)	O
chronic	O
lymphocytic	I:C0023434
leukemia	I:C0023434
(	O
chronic	B:C0023434
lymphocytic	I:C0023434
leukemia	I:C0023434
)	O
.	O

Treatment	B:C0087111
consisted	O
of	O
six	O
monthly	O
courses	O
of	O
the	O
FC	O
regimen	I:C1880651
combined	O
with	O
14	O
days	O
of	O
lenalidomide	O
given	O
at	O
the	O
starting	O
dose	O
of	O
2.5	O
mg	O
during	O
course	O
1	O
.	O

Treatment	O
consisted	O
of	O
six	O
monthly	O
courses	O
of	O
the	O
FC	B:C1880651
regimen	I:C1880651
combined	O
with	O
14	O
days	O
of	O
lenalidomide	O
given	O
at	O
the	O
starting	O
dose	O
of	O
2.5	O
mg	O
during	O
course	O
1	O
.	O

Treatment	O
consisted	O
of	O
six	O
monthly	O
courses	O
of	O
the	O
FC	O
regimen	I:C1880651
combined	O
with	O
14	O
days	O
of	O
lenalidomide	B:C1144149
given	O
at	O
the	O
starting	O
dose	O
of	O
2.5	O
mg	O
during	O
course	O
1	O
.	O

The	O
maximum	O
tolerated	O
dose	O
of	O
lenalidomide	B:C1144149
was	O
5	O
mg	O
.	O

Forty	O
patients	O
were	O
assessed	O
for	O
response	B:C0683154
,	O
66	O
%	O
were	O
IGHV	O
unmutated	O
,	O
45	O
%	O
showed	O
deletion	O
11q	O
or	O
17	O
p	I:C0796349
.	O

Forty	O
patients	O
were	O
assessed	O
for	O
response	O
,	O
66	O
%	O
were	O
IGHV	B:C1415996
unmutated	O
,	O
45	O
%	O
showed	O
deletion	O
11q	O
or	O
17	O
p	I:C0796349
.	O

Forty	O
patients	O
were	O
assessed	O
for	O
response	O
,	O
66	O
%	O
were	O
IGHV	O
unmutated	B:C0243095
,	O
45	O
%	O
showed	O
deletion	O
11q	O
or	O
17	O
p	I:C0796349
.	O

Forty	O
patients	O
were	O
assessed	O
for	O
response	O
,	O
66	O
%	O
were	O
IGHV	O
unmutated	O
,	O
45	O
%	O
showed	O
deletion	B:C0008628
11q	O
or	O
17	O
p	I:C0796349
.	O

Forty	O
patients	O
were	O
assessed	O
for	O
response	O
,	O
66	O
%	O
were	O
IGHV	O
unmutated	O
,	O
45	O
%	O
showed	O
deletion	O
11q	B:C0796366
or	O
17	O
p	I:C0796349
.	O

Forty	O
patients	O
were	O
assessed	O
for	O
response	O
,	O
66	O
%	O
were	O
IGHV	O
unmutated	O
,	O
45	O
%	O
showed	O
deletion	O
11q	O
or	O
17	B:C0796349
p	I:C0796349
.	O

The	O
overall	B:C3272903
response	I:C3272903
and	O
complete	O
remission	O
rates	I:C0544452
were	O
62.5	O
%	O
and	O
22.5	O
%	O
,	O
respectively	O
,	O
the	O
median	O
progression	O
-	O
free	O
and	O
overall	O
survival	O
(	O
OS	O
)	O
were	O
19	O
and	O
45	O
months	O
,	O
respectively	O
.	O

The	O
overall	O
response	I:C3272903
and	O
complete	O
remission	B:C0544452
rates	I:C0544452
were	O
62.5	O
%	O
and	O
22.5	O
%	O
,	O
respectively	O
,	O
the	O
median	O
progression	O
-	O
free	O
and	O
overall	O
survival	O
(	O
OS	O
)	O
were	O
19	O
and	O
45	O
months	O
,	O
respectively	O
.	O

Grade	B:C0001824
3	I:C0001824
-	I:C0001824
4	I:C0001824
granulocytopenia	I:C0001824
was	O
observed	O
in	O
65	O
%	O
of	O
cases	O
,	O
severe	O
infections	O
in	O
7.5	O
%	O
,	O
the	O
lenalidomide	O
-	O
related	O
toxicity	O
was	O
mild	O
.	O

Grade	O
3	I:C0001824
-	I:C0001824
4	I:C0001824
granulocytopenia	I:C0001824
was	O
observed	O
in	O
65	O
%	O
of	O
cases	O
,	O
severe	O
infections	B:C3714514
in	O
7.5	O
%	O
,	O
the	O
lenalidomide	O
-	O
related	O
toxicity	O
was	O
mild	O
.	O

Grade	O
3	I:C0001824
-	I:C0001824
4	I:C0001824
granulocytopenia	I:C0001824
was	O
observed	O
in	O
65	O
%	O
of	O
cases	O
,	O
severe	O
infections	O
in	O
7.5	O
%	O
,	O
the	O
lenalidomide	B:C1144149
-	O
related	O
toxicity	O
was	O
mild	O
.	O

Grade	O
3	I:C0001824
-	I:C0001824
4	I:C0001824
granulocytopenia	I:C0001824
was	O
observed	O
in	O
65	O
%	O
of	O
cases	O
,	O
severe	O
infections	O
in	O
7.5	O
%	O
,	O
the	O
lenalidomide	O
-	O
related	O
toxicity	B:C0013221
was	O
mild	O
.	O

In	O
conclusion	O
,	O
the	O
results	O
of	O
this	O
study	O
demonstrate	O
that	O
low	O
-	O
dose	O
lenalidomide	B:C1144149
associated	O
with	O
the	O
FC	O
schedule	I:C1880651
is	O
an	O
effective	O
treatment	O
for	O
R/R	O
patients	O
with	O
chronic	O
lymphocytic	I:C0023434
leukemia	I:C0023434
,	O
associated	O
with	O
an	O
acceptable	O
safety	O
profile	O
.	O

In	O
conclusion	O
,	O
the	O
results	O
of	O
this	O
study	O
demonstrate	O
that	O
low	O
-	O
dose	O
lenalidomide	O
associated	O
with	O
the	O
FC	B:C1880651
schedule	I:C1880651
is	O
an	O
effective	O
treatment	O
for	O
R/R	O
patients	O
with	O
chronic	O
lymphocytic	I:C0023434
leukemia	I:C0023434
,	O
associated	O
with	O
an	O
acceptable	O
safety	O
profile	O
.	O

In	O
conclusion	O
,	O
the	O
results	O
of	O
this	O
study	O
demonstrate	O
that	O
low	O
-	O
dose	O
lenalidomide	O
associated	O
with	O
the	O
FC	O
schedule	I:C1880651
is	O
an	O
effective	O
treatment	B:C0087111
for	O
R/R	O
patients	O
with	O
chronic	O
lymphocytic	I:C0023434
leukemia	I:C0023434
,	O
associated	O
with	O
an	O
acceptable	O
safety	O
profile	O
.	O

In	O
conclusion	O
,	O
the	O
results	O
of	O
this	O
study	O
demonstrate	O
that	O
low	O
-	O
dose	O
lenalidomide	O
associated	O
with	O
the	O
FC	O
schedule	I:C1880651
is	O
an	O
effective	O
treatment	O
for	O
R/R	O
patients	O
with	O
chronic	B:C0023434
lymphocytic	I:C0023434
leukemia	I:C0023434
,	O
associated	O
with	O
an	O
acceptable	O
safety	O
profile	O
.	O

